Target intelligence / Profile preview

Vestigial-like family member 3 (VGLL3)

Target
VGLL3
Molecular classification
Transcription cofactor, Transcription factor co-activator, Mechanosensitive protein, Vestigial family
01

Overview

Vestigial-like family member 3 (VGLL3) is a transcription cofactor that belongs to the Vestigial family and acts primarily as a partner for TEAD transcription factors, modulating their activity in several tissues[4][7]. VGLL3 is mechanosensitive, with its nuclear localization and function regulated by substrate stiffness[4]. It plays key roles in regulating cell proliferation, differentiation (notably promoting myogenic differentiation and inhibiting adipogenesis), and tissue fibrosis (particularly cardiac and liver fibrosis). In cancer, VGLL3 genomic amplification and overexpression promote tumor cell proliferation and migration, partly by enhancing Hippo pathway signaling to suppress YAP/TAZ activity and by facilitating DNA double-strand repair through proteasomal protection of CtIP[1][3][4][7]. It is highly expressed in certain cancers (e.g., malignant breast tumors, osteosarcoma) and functions as a master regulator in female-biased autoimmunity, as well as in various developmental and stress-response pathways[1][3][5][7].

Other names
Transcription cofactor vestigial-like protein 3Vgl-3VGL3Colon carcinoma related protein
02

Mechanism of action

Modulation of TEAD-dependent gene expression; Activation of Hippo signaling pathway via LATS2 and AMOTL2, leading to YAP/TAZ inactivation; Promotion of DNA repair by protecting CtIP from proteasomal degradation

03

Biological functions

Transcriptional regulation (cofactor for TEAD transcription factors)Cell proliferation regulationMyogenic differentiationInhibition of adipogenesisRegulation of cell fate decisions in mesenchymal lineagesPromotion of collagen synthesis and fibrosisMediation of cellular stress responseRegulation of DNA double-strand break repair
04

Disease associations

Cancer (incl. breast cancer, osteosarcoma, soft tissue sarcoma)Cardiac fibrosisLiver fibrosisAutoimmunity (female-biased)Potential role in adipose tissue disorders
05

Safety considerations

Tumor-promoting activity when overexpressed in certain cancersPotential for enhanced fibrosis in cardiac and hepatic tissues
06

Biomarkers

Overexpression of VGLL3 in malignant breast tumors and osteosarcomaGenomic amplification in soft tissue sarcomas

Beyond the preview

Go deeper on Vestigial-like family member 3 (VGLL3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vestigial-like family member 3 (VGLL3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call